Immunocore Holdings plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Immunocore Holdings plc is a commercial-stage biotechnology company specializing in the development of T-cell receptor (TCR) bispecific immunotherapies, primarily targeting cancer, infectious diseases, and autoimmune conditions. The company’s product portfolio includes its lead approved therapy, KIMMTRAK (tebentafusp), indicated for HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma. Beyond KIMMTRAK, Immunocore is advancing a pipeline comprising multiple clinical-stage candidates including IMC-R117C (PIWIL-1) for advanced solid tumors such as colorectal cancer; IMC-P115C (PRAME-HLE-A02) targeting tumors expressing PRAME; IMC-M113V and IMC-I109V for potential functional cures of HIV and hepatitis B virus respectively; as well as IMC-T119C, IMC-S118AI, and IMC-U120AI addressing solid tumors, type 1 diabetes, and atopic dermatitis. The company leverages its proprietary, off-the-shelf ImmTAX (Immune mobilizing monoclonal TCRs Against X disease) platform to develop these therapies. Founded in 2008 and headquartered in Abingdon, United Kingdom, Immunocore operates primarily in the US and UK markets, with regulatory approvals and commercial launches spanning 39 countries for KIMMTRAK. Recent strategic developments include a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab for advanced cutaneous melanoma. In 2024, Immunocore expanded KIMMTRAK launches into 14 additional countries, reaching 24 countries globally by year-end, driving 30% year-on-year net sales growth and maintaining 11 consecutive quarters of revenue increase. The company also announced a strategic collaboration with Exogene to utilize artificial intelligence for accelerating TCR discovery, enhancing lead candidate generation. Immunocore is progressing multiple Phase 3 trials for cutaneous and adjuvant melanoma with expected data readouts in 2026. They plan to file clinical trial applications for IMC-U120AI in 2026, marking their first non-HLA-restricted universal therapy program. Immunocore’s industry focus lies in biotechnology and life sciences with a core emphasis on innovative immunotherapeutics designed to address significant unmet medical needs. Its customer base primarily encompasses oncology and immunology patients worldwide. The company employs a multidisciplinary approach combining bispecific TCR therapeutics with AI-driven collaboration to accelerate development timelines and broaden therapeutic reach across cancer, infectious, and autoimmune disease segments. Immunocore Holdings plc remains commercially active with a strong commitment to expanding global access to its approved product KIMMTRAK while advancing a robust pipeline aimed at functional cures and novel immunotherapies across multiple disease areas, maintaining its position as a leader in TCR bispecific immune medicines.
Company News
Immunocore to present at upcoming investor conferences
Bank of America Corp DE Trims Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR
Will Kimmtrak Continue to Aid IMCR's Growth Through the Rest of 2026?
IMCR Jumps 21.2% in 3 Months as Kimmtrak Growth Fuels More Momentum
Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?
IMCR Q2 Revenues Climb 18.3% as Kimmtrak Demand Helps Offset EPS Miss
Immunocore's Q2 Earnings Miss Estimates, Kimmtrak Aids Y/Y Revenues
Wall Street Analysts See a 77.91% Upside in Immunocore (IMCR): Can the Stock Really Move This High?
Immunocore Holdings plc (IMCR) Q2 2026 Earnings Call Transcript
Immunocore Q2 Earnings Call Highlights
Immunocore reports second quarter financial results and provides a business update
Immunocore to report second quarter 2026 financial results and host call on August 6, 2026
Immunocore's Kimmtrak Growth Story and Major 2026 Catalysts Ahead
Is Immunocore Stock Attractive After Kimmtrak's Strong Sales Growth?
How Immunocore Is Expanding Beyond Its Rare-Cancer Drug Kimmtrak
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Is it a Good Idea to Invest in Immunocore Stock Right Now?
4 Biotech Stocks Investors Should Watch in 2026
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma
Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma